US Extends Enforcement Discretion For Infant Formula Production With Guidance For Compliance
Executive Summary
Guidance extends through Jan. 6 enforcement discretion for formula products cleared for sales under temporary guidance FDA announced in May. Further extensions possible for firms taking steps toward lawful marketing of products in US, agency says.
You may also be interested in...
US FDA’s Infant Formula Regulatory Authority Doesn’t Reach ‘All That Needs To Be Fixed’
“This system is fundamentally prone to supply chain disruptions with so few manufacturers,” says Mark Moorman, FDA Office of Food Safety director. In FDLI presentation, he acknowledges delicate balance in stemming distribution of potentially contaminated power formula while sustaining supply.
Threat Of Cronobacter Contamination For Powder Infant Formula Rings Clear In Latest US Recall
Reckitt's identification of Cronobacter sakazakii as contaminant in its 145,000-can Enfamil recall is latest clear statement about Cronobacter bacteria potentially disrupting supply of formula and other nutritionals distributed in powder form.
Bioassay Instructions For Tests Using Rats Provided To Bolster US Infant Formula Supply
Draft details modifications to AOAC International’s PER rat bioassay method to show a formula meets quality factor of sufficient biological quality of protein, one factors FDA considers in evaluating submissions.